Seth V Hetherington Net Worth

The estimated Net Worth of Seth V Hetherington is at least $0 dollars as of 9 November 2016. Seth Hetherington owns over 5,000 units of Genocea Biosciences Inc stock worth over $0 and over the last 10 years Seth sold GNCA stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Seth Hetherington GNCA stock SEC Form 4 insiders trading

Seth has made over 4 trades of the Genocea Biosciences Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Seth exercised 5,000 units of GNCA stock worth $10,100 on 9 November 2016.

The largest trade Seth's ever made was exercising 11,000 units of Genocea Biosciences Inc stock on 18 August 2014 worth over $22,220. On average, Seth trades about 3,714 units every 116 days since 2014. As of 9 November 2016 Seth still owns at least 26,000 units of Genocea Biosciences Inc stock.

You can see the complete history of Seth Hetherington stock trades at the bottom of the page.

What's Seth Hetherington's mailing address?

Seth's mailing address filed with the SEC is 100 Acorn Park Dr 5th floor, Cambridge, MA 02140, USA.

Insiders trading at Genocea Biosciences Inc

Over the last 11 years, insiders at Genocea Biosciences Inc have traded over $9,875,933 worth of Genocea Biosciences Inc stock and bought 177,421,644 units worth $259,728,894 . The most active insiders traders include Forest Baskett, Scott D Sandell a Anthony A. Jr. Florence. On average, Genocea Biosciences Inc executives and independent directors trade stock every 27 days with the average trade being worth of $0. The most recent stock trade was executed by Diantha Duvall on 2 June 2022, trading 1,355 units of GNCA stock currently worth $81.

What does Genocea Biosciences Inc do?

Genocea's mission is to conquer cancer by developing personalized cancer immunotherapies in multiple tumor types. Our unique ATLAS™ platform comprehensively profiles each patient's T cell responses to potential targets, or antigens, on the tumor. ATLAS enables us to optimize the neoantigens for inclusion in our immunotherapies and exclude inhibitory antigens, Inhibigens™, that can exert an immunosuppressive effect. We are advancing two ATLAS-enabled programs: GEN-009, our neoantigen vaccine and GEN-011, our neoantigen-specific cell therapy using T cells derived from peripheral blood.

Complete history of Seth Hetherington stock trades at Genocea Biosciences Inc

Genocea Biosciences Inc executives and stock owners

Genocea Biosciences Inc executives and other stock owners filed with the SEC include:

• William Clark,
  President, Chief Executive Officer, Director
• William D. Clark M.B.A.,
  Pres, CEO & Director
• Girish Aakalu,
  Chief Business Officer
• Thomas Davis,
  Chief Medical Officer
• Jessica Flechtner,
  Chief Scientific Officer
• Dr. Thomas A. Davis,
  Chief Medical Officer
• Dr. Girish N. Aakalu Ph.D.,
  Chief Bus. Officer
• Katrine Bosley,
  Independent Director
• Kenneth Bate,
  Independent Chairman of the Board
• George Siber,
  Independent Director
• Michael Higgins,
  Independent Director
• Ronald Cooper,
  Independent Director
• Ali Behbahani,
  Independent Director
• Gisela Schwab,
  Director
• Narinderjeet Singh,
  Senior Vice President - Pharmaceutical Sciences and Manufacturing
• Diantha Duvall,
  Chief Financial Officer
• Dr. Jessica Baker Flechtner,
  Chief Scientific Officer
• Diantha Duvall,
  CFO & Sec.
• Dr. Raymond D. Stapleton Jr.,
  Exec. VP of Pharmaceutical Sciences & Manufacturing
• Jacquelyn L. Sumer,
  Chief Legal & Compliance Officer
• Kevin Bitterman,
  Director
• Jonathan Poole,
  Chief Financial Officer
• Seth V Hetherington,
  Chief Medical Officer
• Paul Giannasca,
  VP of Development
• Stephen J Hoffman,
  Director
• Howard Mayer,
  Director
• Eric S Hoffman,
  Chief Business Officer
• Venture Management Co. V, L...,
  
• John Lunger,
  Director
• Michael Alfieri,
  Principle Financial Officer
• Derek M Meisner,
  SENIOR VP AND GENERAL COUNSEL
• Pamela Carroll,
  SVP IMMUNO-ONCOLOGY
• David M Mott,
  10% owner
• Anthony A. Jr. Florence,
  10% owner
• Scott D Sandell,
  10% owner
• Mohamad Makhzoumi,
  10% owner
• Peter W. Sonsini,
  10% owner
• Joshua Makower,
  10% owner
• Carmen Chang,
  10% owner
• Forest Baskett,
  10% owner
• Peter J Barris,
  10% owner
• Enterprise Associates 16, L...,
  
• Jacquelyn L Sumer,
  CHIEF LEGAL & COMPLIANCE OFF
• Robert E Jr Farrell,
  VP of Finance & Administration
• Venture Management Co. V, L...,
  
• Capital Management, Llc Lux...,
  
• Simeon George,
  Director
• & Johnson Johnson & Johnson...,
  
• Plc Gsk,
  10% owner
• Paul Edward Walker,
  10% owner
• Jennifer Lyn Herron,
  Director
• Raymond D Jr Stapleton,
  CHIEF TECHNOLOGY OFFICER